Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Current Leases (2021 - 2025)

Senti Biosciences has reported Current Leases over the past 5 years, most recently at $5.3 million for Q4 2025.

  • Quarterly results put Current Leases at $5.3 million for Q4 2025, up 14.7% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 14.7% YoY), and the annual figure for FY2025 was $5.3 million, up 14.7%.
  • Current Leases for Q4 2025 was $5.3 million at Senti Biosciences, up from $5.2 million in the prior quarter.
  • Over the last five years, Current Leases for SNTI hit a ceiling of $5.3 million in Q4 2025 and a floor of $96000.0 in Q3 2023.
  • Median Current Leases over the past 5 years was $4.2 million (2024), compared with a mean of $3.5 million.
  • Biggest five-year swings in Current Leases: tumbled 95.01% in 2023 and later skyrocketed 4572.92% in 2024.
  • Senti Biosciences' Current Leases stood at $1.7 million in 2021, then increased by 10.27% to $1.9 million in 2022, then skyrocketed by 109.73% to $4.0 million in 2023, then grew by 15.28% to $4.6 million in 2024, then grew by 14.7% to $5.3 million in 2025.
  • The last three reported values for Current Leases were $5.3 million (Q4 2025), $5.2 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.